Duchenne muscular dystrophy (DMD), a lethal X-linked disorder, is the most common and severe form of muscular dystrophies, affecting 1 in 3,500 male births. Mutations in the DMD gene lead to the absence of muscle dystrophin and a progressive degeneration of skeletal muscle. The possibility to treat DMD through cell therapy has been widely investigated. We have previously shown that human adipose-derived stromal cells (hASCs) injected systemically in SJL mice are able to reach and engraft in the host muscle, express human muscle proteins, and ameliorate the functional performance of injected animals without any immunosuppression. However, before starting clinical trials in humans many questions still need to be addressed in preclinical studies, in particular in larger animal models, when available. The best animal model to address these questions is the golden retriever muscular dystrophy (GRMD) dog that reproduces the full spectrum of human DMD. Affected animals carry a mutation that predicts a premature termination codon in exon 8 and a peptide that is 5% the size of normal dystrophin. These dogs present clinical signs within the first weeks and most of them do not survive beyond age two. Here we show the results of local and intravenous injections of hASCs into GRMD dogs, without immunosuppression. We observed that hASCs injected systemically into the dog cephalic vein are able to reach, engraft, and express human dystrophin in the host GRMD dystrophic muscle up to 6 months after transplantation. Most importantly, we demonstrated that injecting a huge quantity of human mesenchymal cells in a large-animal model, without immunosuppression, is a safe procedure, which may have important applications for future therapy in patients with different forms of muscular dystrophies.
INTRODUCTION
assisted ventilation death due to respiratory or cardiac failure occurs usually before the third decade (6) . The golden retriever muscular dystrophy (GRMD) Progressive muscular dystrophies (PMDs) are a clinically and genetically heterogeneous group of disorders dogs are the closest animal model to DMD. Affected animals carry a frameshift point mutation that causes the caused by the deficiency or abnormal muscle proteins, resulting in progressive degeneration and loss of skeletal skipping of exon 7 and a premature stop codon, resulting in the absence of dystrophin in their muscles. GRMD muscle function. As effective treatments for these diseases are still unavailable, they have been widely inves-dogs and DMD patients have many phenotypic and biochemical similarities, including early progressive muscle tigated as possible candidates for stem cell therapy. Among the different forms, the most frequent and severe degeneration and atrophy, fibrosis, contractures, and elevated serum creatine kinase levels (20) . However, differ-form of muscular dystrophy is Duchenne muscular dystrophy (DMD), a recessive lethal X-linked disease. The ently from the DMD patients, the GRMD dogs show difficulties in swallowing while the loss of ambulation onset is around 3-5 years of age and the clinical course is severe and progressive. Affected boys usually are con-is uncommon. They also show a great clinical variability. Death may occur within the first weeks but is most fined to a wheelchair by 10-12 years of age and without 1408 VIEIRA ET AL. frequent around 1 or 2 years of age as a result of failure dogs, with a protocol comparable to the previously used in the SJL mice model (23) . With this study we aimed of respiratory or cardiac muscles (25) .
Adult skeletal muscle is capable of regeneration by to assess if hASCs are able to migrate, engraft, and differentiate into muscle cells expressing human dystrophin activating a population of muscle cells precursors (19) . However, the continuous and gradual muscle degenera-in a large-animal model. We also analyzed the efficiency of local injections compared to multiple systemic injec-tion in PMDs leads to a depletion of satellite cells and, consequently, the capability to restore the skeletal mus-tions and how long we could detect human cells after the last injection. cle is lost (9,13). One therapeutic approach to treat tentatively PMDs is to use stem cells as precursors to MATERIALS AND METHODS regenerate muscle fibers or compensate for the defective protein expression.
All experiments were approved by the research ethics committee of the Biosciences Institute, University of In the first preclinical trial involving stem cells and GRMD dogs, bone marrow hematopoietic stem cells São Paulo. All human samples were obtained after written informed consent from the donors. All researches were transplanted from normal litter mates to immunosuppressed GRMD dogs, but dystrophin expression was were carried out in the Human Genome Research Center, and the GRMD Genocão (Genedog) kennel at the not restored (3). Subsequently, Sampaolesi et al. (18) reported that the delivery of normal dog mesoangi-Biosciences Institute, University of São Paulo. oblasts to the muscle of dystrophic dogs after intra-arte-hASC Isolation and Expansion rial injection resulted in the restoration of dystrophin expression. The mesoangioblasts show similarities with Human adipose tissue was obtained from elective liposuction procedures. Cells were isolated using meth-human adipose-derived stem cells in size, cell surface protein analysis, proliferation, and differentiation capac-ods previously described (26). Briefly, the unprocessed lipoaspirate was washed extensively with equal volumes ity. All transplanted dogs were maintained on steroids as standard treatment and received immunosuppressant of phosphate-buffered saline (PBS) containing antibiotics (100 U/ml of penicillin and 100 g/ml of streptomy-drugs, which makes it difficult to evaluate clinical results, since it is known that immunosuppressive and cin; Gibco) and then dissociated with 0.075% collagenase (Sigma). Enzyme activity was neutralized with Dulbec-anti-inflammatory drugs can ameliorate the phenotype in muscular dystrophy patients (2) . Our group had pre-co's modified Eagle's media-high glucose (DMEM-HG; Gibco) containing 10% fetal bovine serum (FBS; viously analyzed the result of early systemic delivery of human dental pulp stem cells in GRMD dogs but very Gibco). The infranatant was centrifuged at 1,200 × g for 5 min to pellet the cells. The cells from the pellet stro-few dystrophin-positive-labeled fibers were found in just one injected dog (11). mal vascular fraction (SVF) were filtered to remove debris and seeded in tissue culture plates (NUNC) at An abundant and accessible source of stem cells is adipose tissue. Adipose-derived stromal cells (ASCs) 1,000-3,500 cells/cm 2 in DMEM-LG (low glucose) 10% FBS. Cultures were washed with PBS 24-48 h have the ability to differentiate into skeletal muscle when in contact with dystrophic muscle cells in vitro after plating to remove unattached cells and fed with fresh media. (26) and in vivo (4, 17, 22) . Rodriguez et al. (17) reported that local injections of human ASCs (hASCs) into the The cultures were maintained at 37°C with 5% CO 2 in growth media (GM: DMEM-LG/10% FBS). When muscle of mdx mice (which lack dystrophin), restored dystrophin expression in the area near to the injection they achieved about 70% confluence, the cells were trypsinized (0.025%, TrypLE Express; Gibco) and site. However, the mdx mice have no evident muscular weakness and therefore are not a good model to assess plated at a density of 5,000/cm 2 . Cultures were passaged repeatedly after achieving a density of 70-80% until potential functional effects of stem cell therapy. We have previously shown that hASCs injected systemically passage 4. The remaining cells were cryopreserved in cryopreservation media (10% dimethyl sulfoxide, 10% in SJL mice, a murine model for Limb-Girdle muscular dystrophy type 2B (LGMD2B), were able to reach the DMEM-LG, 80% FBS), frozen at −80°C in isopropanoljacked closed container, and stored in liquid nitrogen the host muscle, engraft, express human muscle proteins, and ameliorate their functional performance (23) . These next day. results led us to investigate if the hASCs have a compa-Flow Cytometry rable behavior in the closest animal model to human DMD, the GRMD dog.
The flow cytometry was performed on Guava Easy Cyte System (Guava Technologies) using a blue laser Here we show for the first time the results obtained with systemic transplantation of hASCs, with no immu-(488 nm). Cells were pelleted, resuspended in PBS at concentration of 10 5 cells/ml, and stained with saturating nosuppression, in four affected male littermate GRMD concentration of antibodies. Cells were incubated in the Local Transplantation dark for 45 min at room temperature. After incubation, Two female 2-year-old affected dogs, from another cells were washed three times with PBS and resuspended litter, received a single injection of 10 7 cells in 0.1 ml in 0.25 ml of cold PBS. Cell viability was accessed with of HBSS into the right hind limb biceps femoralis. Guava ViaCount reagent (Guava Technologies).
Muscle Biopsies hASCs were incubated with the following primary antibodies: human leukocyte antigen-DR-phycoerythrin Biceps femoralis biopsy samples were taken from all (HLA-DR-PE), HLA-ABC-fluorescein isothiocyanate dogs after hASCs transplantation. (FITC), cluster of differentiation 13 (CD13)-PE, CD29-In dogs systemically injected, the muscle biopsies phycoerythrin cyanine 5 (PECy5), CD31-PE, CD34-periwere taken before and after the injected period; DNA dinin chlorophyll protein complex (PerCP), CD44-FITC, and muscle dystrophin were analyzed in autopsied mus-CD45-FITC, CD73, CD90-PE, CD105, and CD117cle while in the two dogs that are still alive, Yuan and PE (Becton Dickinson). Unconjugated markers were Dolar, muscle biopsies were taken before the hASC reacted with anti-mouse PE secondary antibody transplantation, 2 months, 6 months, and 1 year after the (Guava Technologies).
last injection. Samples of biceps femoralis from a nor-Flow cytometer gates were set using unstained cells.
mal and GRMD dogs of a comparable age were cryopro-Cells were gated by forward scatter to eliminate debris.
tected and frozen in liquid nitrogen and used as controls. To eliminate the possible autofluorescence of ASCs, we
In the two female dogs that received local injections removed the contribution of unstained cells in the meainto their right hind limb muscle biopsies from both hind surement channel. A minimum of 10,000 events was limb biceps femoralis were taken 1 month after being counted for each analysis.
injected, the left hind limb muscle sample was used as noninjected control.
Multilineage Differentiation
Human DNA Analysis Before injections, the cells were analyzed for their
The DNA was obtained using DNeasy Blood & Tiscapacity to differentiate toward adipogenic, osteogenic, sue Kit (Qiagen). The presence of human DNA in the chondrogenic, and myogenic lineages as described in host samples were evaluated as described in Pelz et al. Zuk et al. (26). (16) . Centromeric region of human chromosome 7 and the dog dystrophin gene was amplified by PCR (35 Animals cycles, annealing at 59°C). Primers sequences were as follows: human chromosome 7 sense: AGCGATTTGA All animals were housed and cared for in the Univer-GGACAATTGC and antisense: CCACCTGAAAATG sity of São Paulo and genotyped at birth as previously CCACAGC; dog dystrophin gene (10): sense: CTTAA described (10). GRMD dogs were identified by micro-GGAATGATGGGCATGGG and antisense: ATGCAT chips. Animal care and experiments were performed in AGTTTCTCTATCATGC. The PCR products were sepaccordance with animal research ethics committee of the arated by electrophoresis on 2% agarose gels and stained Biosciences Institute, University of São Paulo. A total with ethidium bromide. Nonsaturated digital images of seven dogs were used in this study.
were obtained using an ImageQuant imaging system (GE HealthCare).
Systemic Transplantation
Immunofluorescence (IF) and Histology Four 2-month-old male dogs were transplanted and one carrier female was maintained as normal control. To
Muscle samples were frozen in liquid N 2 . Sections (7 µm) were used for routine histology and immunohisto-minimize the effects of variability previously observed in GRMD dogs we used animals from the same litter chemistry. Hematoxylin and eosin stain was carried out for morphology studies. Each sample was analyzed by ( Fig. 1 ). Each animal was injected in the cephalic vein with 5 × 10 7 cells kg −1 in 0.1 ml of Hank's buffered salt two different and independent persons in a blind test. Muscle cryosections were fixed in 4% paraformalde-solution (HBSS). Four animals were injected for 6 months, weekly in the first month and then monthly, hyde in PBS for 20 min at 4°C, permeabilized in 0.05% Triton X-100 in PBS for 5 min. Nonspecific binding was receiving a total of nine injections. The cells were injected right after their preparation. One dog (II-8) died blocked with 10% FBS in PBS for 1 h at room temperature. Muscle sections were incubated with primary anti-at 4 months old, 1 week after the sixth injection, and another (II-11) at 7 months old, 1 week after the eighth body overnight at 4°C and with secondary antibody for 1 h at room temperature. The following primary antibod-injection. The two dogs that are still alive are currently 34 months old.
ies were used: anti-human-dystrophin Mandys1062C6 tive bands were detected with ECL chemiluminescence detection system (GE Healthcare).
RNA Isolation and RT-PCR
Quantitative analysis of human dystrophin at the host Total RNA was harvested from the human cell-transmuscle was performed by using the ImageJ software planted dog muscle biopsies using Tryzol (Invitrogen) (http://rsb.info.nih.gov/ij/), using myosin at the Ponceau following the manufacturer's instructions. The RNA staining as a protein loading control. was treated with DNase (Invitrogen). A total of 1 µg of total RNA was reverse-transcribed with SuperScript TM RESULTS III First-Strand Synthesis System (Invitrogen). All
Characterization of hASCs amplifications were performed in an MJ Research PTC-hASCs were previously characterized (23) by flow 200 thermocycler (MJ Research) for 30 cycles after the cytometry for the expression of 12 cell surface proteins initial 2-min denaturation at 94°C. Primer sequences for (HLA-DR, HLA-ABC, CD13, CD29, CD31, CD34, human genes (except for dog β-actin) were as follows:
CD44, CD45, CD73, CD90, CD105, and CD117). Cell myogenin: sense CAGCTCCCTCAACCAGGAG and viability was above 96% by Guava ViaCount reagent antisense: CGCTGTGAGAGCTGCATTC; myogenic (Guava Technologies). factor 5 (Myf5) sense: TTTGACAGCATCTACTGTC At passage 4, hASCs did not express either endothe-CTGA and antisense: GAGGTGATCCGGTCCACT lial markers [CD31-platelet/endothelial cell adhesion ATGT; β-actin: sense: AAGATGACCCAGATCATGT molecule (PECAM1)] or hematopoietic markers (CD34, TCG and antisense: GGAGTCCATCACGATGCCAGT.
CD45, and CD117-c-kit). The majority of hASCs The PCR products were analyzed by electrophoresis of expressed high levels of CD13, CD44, adhesion markers 5 µl aliquots in 2% agarose gel, and the amplicons were [CD29-integrin-β1, CD90-thymocyte differentiation visualized by ethidium bromide staining.
antigen-1 (Thy-1)], and mesenchymal stem cell marker Western Blot (WB) Analysis CD73 (ecto-5′-nucleotidase). Expression of some markers, such as CD105 (endoglin), was variable among the Muscle sample proteins were extracted through treatment with a buffer containing 10 mM Tris-HCl (pH 8.0), donors. hASCs were negative for HLA-class II (HLA-DR), but positive for HLA-class I (HLA-ABC) (data 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 60 mM octylglucoside. Samples were centrifuged at not shown). The plasticity of hASCs was assessed 3 weeks after 13,000 × g for 10 min to remove insoluble debris. Soluble proteins were resolved by 6% sodium dodecyl sul-lineage induction (23) . Myogenic, adipogenic, chondrogenic, and osteogenic differentiation was demonstrated fate-polyacrylamide gel electrophoresis (SDS-PAGE), by the expression of myogenic markers (myosin and muscle sample, was: 11% in Dolar (II-6) and 16% in Yuan (II-7); and six months after the last injection: 15% desmin), lipid vacuoles, mucopolysaccharide-rich extracellular matrix, and calcium deposits, respectively.
in Dolar (II-6) and 19% in Yuan (II-7). No dystrophin was found 1 year after the last injection ( Fig. 3C) . At These results confirmed the mesenchymal nature of the isolated cells as well as their multipotent potential (data the necropsied muscles, Peso (II-8), which received only six injections, showed 6% expression of human dys-not shown).
trophin; Real (II-11), which received eight injections, hASC Capacity to Reach and Engraft showed 15% expression of human dystrophin in its necat the Host Muscle ropsied muscle (Fig. 3D) , both compared to a normal muscle dystrophin expression. In order to assess the potential of hASCs to reach and colonize the host muscle we injected undifferentiated A modest number of labeled fibers by immunofluorescence (IF) analysis in the injected animals using the hASCs, previously characterized by flow cytometry and differentiation potential (23), into the cephalic vein of anti-human dystrophin antibody was also observed, which are compatible with the WB results ( Fig. 3E ). four dogs. One uninjected GRMD carrier female from the same litter was analyzed as age-matched normal Histopathological Analysis control. Two dogs (Peso, II-8 and Real, II-11) were euthanized due to hiatal hernia. Peso (II-8) died at 4
Histopathological analysis of skeletal muscles from injected dogs showed a typical dystrophic pattern months old, 1 week after the sixth injection, and Real (II-11) died at 7 months old, 1 week after the eighth including size variation among individual muscle fibers, fiber splitting, small regenerated basophilic fibers, injection. The two dogs that are still alive are currently 34 months old. In order to compare the results of sys-numerous fibers with centrally located myonuclei, and significant connective tissue replacement (Fig. 4 ). temic injections versus local delivery we injected two homozygous affected GRMD females from another litter DISCUSSION at the biceps femoralis.
The PCR method as previously reported by Pelz et The role of mesenchymal stem cells (MSCs) in clinical applications for progressive muscular dystrophies al. (16) was used to evaluate the presence of human cells in the biceps femoralis of the systemically and locally (PMD) is still controversial. According to some authors these cells would mediate tissue repair through their injected animals. All systemically injected animals showed human DNA in the biceps femoralis ( Fig. 2A) . multilineage differentiation potential, enabling them to replace damaged cells. Others suggest that this mecha-However we did not find human DNA in any of the locally injected muscles (Fig. 2B) .
nism is unlikely and believe that in response to tissue injury, MSCs home to the site of damage and enhance Immunofluorescence analysis with anti-human nuclei antibody also showed a few positive labeled nuclei in repair through the production of trophic factors. These include growth factors, cytokines, and antioxidants, systemically injected animals (Fig. 2C) . some of which provide the basis for their capacity to Expression of Human Muscle Proteins modulate immune responses (7) . in the Host Muscle Two different authors reported that ASCs are able to differentiate in vivo when injected directly into the mus-To explore the expression of human muscle proteins after the engraftment of hASCs we analyzed the presence cle of the mdx mouse (4,17). According to Rodriguez et al. (17), local injections of hASCs into immunocompe-of mRNAs of the following human muscle proteins: myogenin, Myf5, and dystrophin, at the host muscle, by RT-tent mdx mouse muscle results in a huge dystrophin expression. Subsequently, we reported that hASCs are PCR. Human muscle proteins were found in muscle samples of all injected animals (Fig. 3A) .
not rejected when transferred systematically to the SJL mice without any immunosuppression. These cells were To evaluate the presence of human dystrophin in GRMD host muscles we used a specific human-dystro-able to fuse with the host muscle cells, express human skeletal muscle proteins and improve the motor ability phin antibody (21). No human DNA was found at the injected muscles following local injections, and as of affected animals. Although the SJL mice have a mild phenotype we observed functional improvement of the expected, no positive dystrophin bands were observed by WB as well (Fig. 3B) . Human dystrophin expression, injected animals after 6 months of in vivo treatment, which was encouraging (23) . which was found until 6 months after the last injection, varied from 11% to 19% in the two systemically injected A significant obstacle in designing cell therapy for PMDs is the necessity to reach the entire body muscula-animals that were submitted to the entire protocol of nine injections. Two months after the last injection, dys-ture, a problem that cannot be easily overcome unless systemic cell delivery methods of a large number of trophin expression, when compared to a human normal cells are proved to be effective. The GRMD dog, which last injections. These dogs are currently 34 months old and healthy. has the weight of an 8-year-old child, is the closest animal model for DMD. They develop progressive, fatal This result indicates that a huge quantity of hASCs cells can be xenotransplanted systemically, and repeat-disease strikingly similar to human condition in many aspects. Therefore, studies in GRMD dogs are more edly, in nonimmunosuppressed animals without rejection. On the other hand, in contrast to our previous likely than those in mouse models to predict pathogenesis and treatment outcome in DMD (12). Since autolo-observations in mdx mice (17), we observed that hASCs injected locally into the biceps femoralis of two other gous cell therapy for DMD requires genetic modification, preclinical studies with heterologous stem cells in a GRMD dogs, in an amount comparable to what had been injected in mice, were not found in the host muscle larger animal model for muscular dystrophies are of utmost importance. Therefore, we have repeated the after 1 month. One possibility is that local injections might trigger a different reaction against injected cells same experiment done with SJL mice in GRMD dogs, injecting a comparable quantity of cells based on their than systemic delivery. Alternatively, different cell concentrations (and/or injection protocols) may be required weight (5 × 10 7 cells kg −1 ).
Here we show for the first time that a huge amount to express dystrophin in the GRMD model, since in the case of systemic delivery the dogs received nine injec-of hASCs delivered systemically into GRMD dogs is able to reach and express human dystrophin in the host tions compared to only one local injection. In any case, this observation suggests that the systemic delivery of muscles, without immunosuppression. Although two dogs died, of hiatal hernia, a frequent cause of death in hASCs might be more effective than local delivery to reach and engraft into the host muscles, in accordance GRMD dogs (Joe Kornegay, personal communication) most likely unrelated to the stem cell transplantation, to our previous results with human dental pulp stem cells (11). It is important to point out that although we human dystrophin was found in their necropsied muscle. In the two dogs that are alive, Yuan and Dollar, muscle did not find human dystrophin 1 year after the last injection, the condition of the two dogs is still stable 27 biopsies were repeated 2, 6, and 12 months after the last injection. Human dystrophin was not found after 12 months after the last injection. These results, if confirmed, suggest that biannual systemic injections would months but it was still present 2 and 6 months after the be required for the maintenance of injected cells in the after the end of the protocol. It will be extremely important to repeat this experiment in a larger number of ani-host muscles if used therapeutically.
Recent reports on the recovery of dystrophin expres-mals that are followed for longer periods to assess if this occurred as a result of cell transplantation, a better clini-sion and functional impact of stem cell transplantation in PMD animal models have shown different results. We cal management, or due to the natural history associated with a great phenotypic variability in GRMD dogs. observed an improvement in the performance of the SJL mice after the transplantation of hASCs (23) but not Therapeutic approaches for DMD have analyzed their success based on dystrophin expression at the dystrophic after the transplantation of human umbilical cord mesenchymal stromal cells in the same animal model (24) . muscle. However, different studies have shown that the rescue of dystrophin expression may not result in clini-Other researchers reported no functional improvement in the mdx mice after the transplantation of bone marrow cal improvement (8,12). In addition, it is well known that the mdx mice are almost asymptomatic despite the mesenchymal stem cells, even after expressing dystrophin (8).
absence of muscle dystrophin. Most importantly, we have reported that a milder phenotype can occur in Dystrophin expression following different therapeutic approaches has been used as a marker to assess the GRMD dogs despite the complete absence of muscle dystrophin (25) , which has also been described in a 7-presence of exogenous cells in the injected animals. A widespread muscle expression of an AAv9 human mini-
year-old DMD boy (5) and more recently in Labrador retriever muscular dystrophy (LRMD) dogs (Diane dystrophin vector following intravenous injections in three neonatal dystrophin-deficient dogs was recently Shelton, personal communication). The fact that is possible to find a milder phenotype in large-animal models reported. At the end of 16 weeks, two out of three dogs showed generalized expression of minidystrophin in and humans indicates that other still unknown factors, in addition to muscle dystrophin, may play a key role in 15% to nearly 100% of myofibers. However, although there was a widespread muscle expression of minidys-muscle recovery and function. Muscle degeneration associated with DMD is a com-trophin, the affected dogs had pelvic limb girdle muscle atrophy and contractures, apparently associated with an plex process in which inflammatory events play a major role in disease progression. hASCs are known to have early innate immune response (12). In another study, patients with frameshifting deletions in the DMD gene, an enhanced immunosuppressive capacity under inflammatory conditions, without losing their differentiation who were injected with functional minidystrophin incorporated by recombinant adeno-associated virus (rAAV), capacity (1) . A growing body of evidence suggests that MSCs have the capacity to modulate immune responses showed autoreactive dystrophin-specific T cells. The authors suggest that monitoring of cellular immune via direct and indirect interactions with a broad range of cell types (7, 15) . These observations indicate that the responses should be a priority for any experimental therapy in PMDs (14). Different from these two studies, success of therapeutic trials should not be based solely on the molecular analysis to assess the rescue of the here the injected stem cells carried a normal length human dystrophin gene. The fact that we found a small defective muscle protein expression. Long-term followup is mandatory before reaching any conclusions. Fur-quantity of human dystrophin, ranging from 6% to 19% through WB and weak IF staining is not surprising tak-ther in vivo studies, which are currently under way, aiming to elucidate the immunologic effects of hASC ing into account that the procedure involved xenotransplantation in a large-animal model. Also the observation transplantation and dystrophin expression will be essential before starting any therapeutic trial in DMD patients. that no human dystrophin was found after 12 months may suggest that hASCs are not replacing the satellite
In short, here we show for the first time that undifferentiated hASCs are not rejected when systematically cell niche at the muscle, at least with the injection protocol here used. administered intravenously to the GRMD dog without immunosuppression, and are able to differentiate in the Muscles of injected animals did not show any improvement in their histopathological pattern. Since host muscle and express human dystrophin for at least 6 months after the last injection. Our results also showed GRMD dogs show a huge phenotypic variability, it is difficult to assess if the transplantation of hASCs had an that multiple injections, with intervals of no longer than 6 months, may be required to maintain the presence of effect on the course or survival of the injected dogs. The two dogs that died of hiatal hernia, before the end of the exogenous dystrophin. We also observed that no human DNA or dystrophin was found in the host muscles fol-protocol, did not have the chance to benefit from the whole procedure. Yuan (II-7) and Dolar (II-6), currently lowing one local injection. These results open new avenues for preclinical aged 34 months, are being followed in our kennel. Dolar always had a milder phenotype, while Yuan, who was research that may have important applications for future therapy with the advantages that: a) it may be applicable more severely affected, showed an apparent improvement
